Format

Send to

Choose Destination
ESMO Open. 2018 Feb 2;3(2):e000285. doi: 10.1136/esmoopen-2017-000285. eCollection 2018.

Global cancer control: responding to the growing burden, rising costs and inequalities in access.

Author information

1
Department of Medicine I, Comprehensive Cancer Center Vienna, Medical University of Vienna, Vienna, Austria.
2
Instituto CUF Oncologia, NOVA Medical School, Lisboa, Portugal.
3
Faculty Hospital Trencin, Trencin, Slovakia.
4
Department of Oncology, Odense University Hospital, Odense, Denmark.
5
Division of Early Drug Development for Innovative Therapies, Istituto Europeo di Oncologia, Milano, Lombardia, Italy.
6
Ankara Oncology Education and Research Hospital, Ankara, Turkey.
7
Division of Medical Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands.
8
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Spain.
9
Institut de Cancerologie de l'Ouest Saint-Herblain, Quest Saint-Herblain, France.
10
Medical School, National and Kapodistrian University of Athens, Athens, Greece.
11
Iridium Cancer Network, AZ KLINA Hospitals, Brasschaat, Belgium.
12
Department of Medical Oncology, Ankara Numune Education and Research Hospital, Ankara, Turkey.
13
Fondazione IRCCS Istituto Nazionale Tumori Milano, Milano, Italy.
14
Royal Marsden Hospital NHS Foundation Trust, London, UK.
15
Università degli Studi della Campania Luigi Vanvitelli, Naples, Italy.
16
Cancer Institute "Ion Chiricuta", Cluj-Napoca, Romania.
17
Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Universitat Autònoma de Barcelona, Barcelona, Spain.
18
Comprehensive Cancer Center, Medical University Vienna, General Hospital, and Vienna Cancer Center, Vienna, Austria.
19
Istituto Nazionale Tumori, Milan, Italy.
20
Breast Unit, Champalimaud Clinical Center, Lisbon, Portugal.
21
European Society for Medical Oncology, Lugano, Switzerland.
22
Cancer Control, Management of Noncommunicable Diseases Unit Department for Management of Noncommunicable Diseases, Disability, Violence and Injury Prevention (NVI), World Health Organization, Geneva, Switzerland.

Abstract

The cancer burden is rising globally, exerting significant strain on populations and health systems at all income levels. In May 2017, world governments made a commitment to further invest in cancer control as a public health priority, passing the World Health Assembly Resolution 70.12 on cancer prevention and control within an integrated approach. In this manuscript, the 2016 European Society for Medical Oncology Leadership Generation Programme participants propose a strategic framework that is in line with the 2017 WHO Cancer Resolution and consistent with the principle of universal health coverage, which ensures access to optimal cancer care for all people because health is a basic human right. The time for action is now to reduce barriers and provide the highest possible quality cancer care to everyone regardless of circumstance, precondition or geographic location. The national actions and the policy recommendations in this paper set forth the vision of its authors for the future of global cancer control at the national level, where the WHO Cancer Resolution must be implemented if we are to reduce the cancer burden, avoid unnecessary suffering and save as many lives as possible.

KEYWORDS:

cancer treatment inequalities; global cancer burden; global cancer control

Conflict of interest statement

Competing interests: AE: Currently conducting research sponsored by AstraZeneca, Pfizer, Celltrion, Novartis, Roche. JT: Advisory Boards for Amgen, Bayer, Boehringer Ingelheim, Celgene, Chugai, Genentech, Lilly, MSD, Merck Serono, Novartis, Pfizer, Roche, Sanofi, Symphogen, Taiho, and Takeda. FCi: Advisory Boards: Merck Serono, Amgen, Roche, Bayer, Lilly, Servier. Research funding: Bayer, Roche, Merck Serono. GP: Honorarium for advisory boards or speakers fee: Roche, Celgene, Shire, Merck, Amgen, Lilly, BMS, Servier, Taiho, Halozyme, Sanofi. PC: Honoraria for consultancy/advisory role and/or for lectures from: Bayer, Blueprint Medicines, Deciphera Pharmaceuticals, Eisai, Eli Lilly, Nektar Ther., Novartis, Pfizer, PharmaMar. At his institution, his Unit received funds for research from: AmgenDompé, Arog Pharmaceuticals, Bayer, Eisai, Eli Lilly, Daiichi Sankyo Pharma, Epizyme Inc., Novartis, PharmaMar. MS: Conducts research sponsored by Janssen Pharmaceuticals. Advisory Boards: BMS, Novartis, Janssen Pharmaceuticals, Leo Pharma. Speaker bureau for BMA, Novartis. Travel funding: Novartis, BMS, Astellas, Ipsen. All other authors declare no competing interests related to this paper.

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center